Detalhe da pesquisa
1.
Microbiome and Anticancer Immunosurveillance.
Cell
; 165(2): 276-87, 2016 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27058662
2.
Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.
Immunity
; 53(4): 824-839.e10, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33053331
3.
Differential expression of the immunosuppressive enzyme IL4I1 in human induced Aiolos+, but not natural Helios+, FOXP3+ Treg cells.
Eur J Immunol
; 45(2): 474-9, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25446972
4.
Links between genetics and immunology: mutations and antigens.
Bull Acad Natl Med
; 200(1): 67-79, 2016 Jan.
Artigo
em Inglês, Francês
| MEDLINE | ID: mdl-29889414
5.
Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1ß by downregulating their suppressor functions.
J Immunol
; 191(9): 4619-27, 2013 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24068664
6.
MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.
Haematologica
; 98(2): 316-22, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22875619
7.
Ex vivo IL-1 receptor type I expression in human CD4+ T cells identifies an early intermediate in the differentiation of Th17 from FOXP3+ naive regulatory T cells.
J Immunol
; 187(10): 5196-202, 2011 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21998454
8.
Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors.
Proc Natl Acad Sci U S A
; 107(45): 19402-7, 2010 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-20962281
9.
Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.
Proc Natl Acad Sci U S A
; 107(16): 7437-42, 2010 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20368442
10.
Distant antimetastatic effect of enterotropic colon cancer-derived α4ß7+CD8+ T cells.
Sci Immunol
; 8(84): eadg8841, 2023 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37289857
11.
Immune changes in hilar tumor draining lymph nodes following node sparing neoadjuvant chemoradiotherapy of localized cN0 non-small cell lung cancer.
Front Oncol
; 13: 1269166, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38074683
12.
Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t.
Proc Natl Acad Sci U S A
; 106(21): 8635-40, 2009 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-19439651
13.
Circulating Exhausted PD-1+CD39+ Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade.
Cancers (Basel)
; 14(15)2022 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35954341
14.
Comment on "differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors".
J Immunol
; 193(7): 3181, 2014 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25240015
15.
Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?
Front Oncol
; 11: 662236, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33968769
16.
Phased differentiation of γδ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers.
Oncoimmunology
; 10(1): 1939518, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34721945
17.
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial.
Clin Cancer Res
; 27(4): 1037-1047, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33272982
18.
PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.
JCI Insight
; 6(2)2021 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33332284
19.
Comment on "helios+ and helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans".
J Immunol
; 190(9): 4439-40, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23606718
20.
HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Clin Cancer Res
; 15(1): 299-306, 2009 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19118058